Revenue segments as reported by the company.

U.S. Pharmaceutical

Prescription Technology Solutions

Medical-Surgical Solutions

International

Corporate

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, distribution, general, and administrative expenses

Claims and litigation charges, net

Restructuring, impairment, and related charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

McKesson

McKesson Corp. engages in the provision of supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. It operates through the following segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products, provides practice management, technology, clinical support, and business solutions to community-based oncology, and other specialty practices, and sells financial, operational, and clinical solutions to pharmacies and provides consulting, outsourcing, technological, and other services. The International segment provides distribution and services to wholesale, institutional, and retail customers in European countries and Canada. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The RxTS segment brings together CoverMyMeds, RelayHealth, RxCrossroads, and McKesson Prescription Automation, including Multi-Client Central Fill as a Service, to serve biopharma and life sciences partners and patients. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

McKesson reports robust fiscal 2023 performance and focuses on sustainability

McKesson's Q4 fiscal 2023 earnings call highlighted strong financial performance, strategic priorities, and a focus on sustainability and employee recognition. The company faces challenges related to operational efficiencies and managing potential impacts from industry dynamics. However, it remains optimistic about opportunities for long-term growth and partnerships in the oncology space.

McKesson reports strong Q1 performance and anticipates sustained growth

McKesson's Q1 fiscal 2024 earnings call showcased strong financial performance, with a focus on prescription volume growth and expansion in the U.S. Oncology Network. The company faces potential fluctuations and timing challenges in its RxTS business but expects to benefit from volume-related factors and continual development. Overall, McKesson is well-positioned for sustainable growth and value creation.

McKesson excels in Q3, eyes oncology growth and sustainability

McKesson's Q3 performance was strong, with raised guidance and progress in strategic priorities.
The company's strengths lie in its focus on oncology, sustainability initiatives, and operational performance.
Challenges include macroeconomic factors, biosimilar management, and margin improvement strategies.
Opportunities in oncology growth, biosimilars, and strategic partnerships pave the way for future success.

McKesson reports robust earnings, poised for sustainable growth in healthcare

McKesson's Q4 2023 earnings call highlighted strong financial performance, strategic advancements, and a commitment to driving sustainable growth in key healthcare segments.
The company's focus on efficiency, sustainability, and employee engagement underpins its competitive strengths and resilience in a dynamic healthcare landscape.
While challenges such as industry fluctuations and regulatory dynamics exist, McKesson's strategic positioning, diverse business lines, and growth opportunities position it for continued success.
By leveraging opportunities in service expansion, biosimilars, and market trends, McKesson aims to enhance patient outcomes, drive revenue growth, and maintain its leadership in the healthcare services sector.

McKesson exceeds Q1 expectations, focuses on supply chain efficiency

McKesson delivered strong first-quarter results, exceeding revenue and earnings expectations.
The company's focus on enhancing supply chain efficiency and expanding relationships with manufacturers is driving growth.
Challenges include non-linear investments and the impact of 340B on pharmaceutical distribution business.
Opportunities lie in benefiting from volume-related factors, supporting product life cycles, and expanding oncology solutions.

McKesson excels in Q2, anticipates growth amid strategic investments

McKesson's Q2 performance reflects strong revenue growth and operational excellence across key segments.
The company's focus on employee well-being, technology solutions, and strategic investments positions it for continued success.
While facing competitive challenges in generics procurement, McKesson maintains stability and customer-centric supply.
Anticipated growth opportunities in fiscal 2024 and beyond underscore McKesson's commitment to innovation and operational efficiency.

McKesson reports robust Q3 earnings, eyes growth through strategic investments

McKesson's Q3 performance reflects strong revenue and earnings growth, supported by strategic initiatives and investments in key segments. While facing challenges like patient visit volumes and margin pressures, the company remains focused on driving sustainable growth and value delivery. Opportunities for growth through technology investments and segment expansions position McKesson for future success.

McKesson reports robust Q4 results, eyes growth in oncology services

McKesson's strong performance in Q4 '24 underscores its leadership in oncology and biopharma services, supported by strategic investments in AI and a new partnership with Optum. While facing challenges in pricing dynamics and 3PL business growth, the company is well-positioned to capitalize on opportunities in inorganic growth, AI utilization, and health equity initiatives.

McKesson reports solid Q1 growth, focuses on pharma innovation

McKesson's Q1 2025 showed solid revenue growth and increased earnings per share, driven by strong performance in pharmaceutical segments.
While facing challenges in the Medical-Surgical segment, the company aims to leverage strengths in distribution and technology investments for future growth.
Opportunities lie in capitalizing on pharmaceutical segment performance and driving innovation through technology investments.
Overall, McKesson's outlook for fiscal 2025 remains positive with projected revenue and profit growth.

McKesson posts record revenue, focuses on oncology for sustained growth

McKesson's strong financial performance and raised guidance reflect its resilience and strategic focus on growth.
While facing regulatory and integration challenges, the company's commitment to innovation and employee well-being positions it well for the future.
Opportunities lie in expanding market presence through acquisitions, influencing policy reforms, and optimizing operational efficiencies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

McKesson Corp. engages in providing healthcare services. It operates through the following segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs. The RxTS segment offers prescription price transparency, benefit insight, dispensing support services, third-party logistics, and wholesale distribution. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The International segment refers to the distribution and services to wholesale, institutional, and retail customers in Europe and Canada. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.

Associated Banc-Corp

Brookfield Asset Management

Brookfield Infrastructure Partners L.P.

Bank of Hawaii

Cable One

Cboe Global Markets

Cullen/Frost Bankers

Dover

FNCB Bancorp

Goldman Sachs

Mercantile Bank

MGE Energy

Martin Marietta Materials

MVB Financial

NBT Bancorp

North American Energy Partners

Peoples Bancorp of North Carolina

Principal Financial Group

Peoples Financial Services

STERIS

All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. They have an average increase of 10.3% and a median increase of 6.7%.

21 Upcoming Dividend Increases Including 1 Dividend King

The market is 29% overvalued and full of crazy speculative bubbles.

McKesson Is Up 73% But Set To Soar Even More

Arbor Realty Trust

Cintas Corp

Hershey

KLA-Tencor

Mondelez

MSCI

Norfolk Southern

Republic Services

Scotts Miracle-Gro

This weekly article series covers dividend changes. A table with relevant data and key statistics of dividend increases is provided.

Dividend Increases: July 24-30, 2021

McKesson's (MCK) fiscal first-quarter 2022 results benefit from strong performance across all segments.

McKesson (MCK) Earnings and Revenues Beat Estimates in Q1

McKesson Corp (NYSE: MCK) reported first-quarter FY22 adjusted EPS of $5.56, almost doubled from $2.77 a year ago, and easily beating the analyst consensus of $4.17. Revenues increased 13% Y/Y to $62.67 billion, surpassing the consensus of $59.9 billion, driven by higher volumes from retail national account customers and market growth, partially offset by branded to generic conversions.

McKesson Q1 Earnings Surpass Wall Street Estimate; Raises FY22 EPS Outlook

McKesson Corporation (MCK) CEO Brian Tyler on Q1 2022 Results - Earnings Call Transcript

McKesson (MCK) delivered earnings and revenue surprises of 35.94% and 5.16%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

McKesson (MCK) Q1 Earnings and Revenues Surpass Estimates

Shares of McKesson (NYSE:MCK) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 100.72% year over year to $5.56, which beat the estimate of $4.17.

Recap: McKesson Q1 Earnings

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2022 first-quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, August 4th at 4:30 PM ET to review its financial results. The live webcast will be available on McKesson's Investor Relations

McKesson Reports Fiscal 2022 First-Quarter Results

McKesson's (MCK) fiscal first-quarter results are likely to reflect solid show by U.S. Pharmaceutical and Specialty Solutions segment.

McKesson (MCK) to Report Q1 Earnings: What's in the Offing?

IRVING, Texas--(BUSINESS WIRE)--The Board of Directors of McKesson Corporation (NYSE:MCK) declared on July 23, 2021 a regular dividend of $0.47 per share of common stock, a 12% increase from $0.42 per share in the prior quarter. The dividend will be payable on October 1, 2021, to stockholders of record on September 1, 2021. About McKesson Corporation McKesson Corporation is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, a

McKesson Raises Quarterly Dividend by 12% to $0.47 Per Share

Amgen

Cardinal Health

Newell Brands

Starbucks

These companies could borrow money at lower rates and use the proceeds to buy back stock—making their shares more attractive to investors.

5 Stocks to Play Low Interest Rates—While They Last

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) (the “Company”) today announced the determination of the Full Tender Offer Consideration, as shown in the table below, for its previously announced cash tender offer to purchase up to $500,000,000 aggregate principal amount (the “Offer”) of its outstanding 6.00% Notes due 2041 (the “6.00% Notes”), 4.883% Notes due 2044 (the “4.883% Notes”), 7.65% Debentures due 2027 (the “7.65% Debentures”), 4.750% Notes due 2029 (the “4.750% Note

McKesson Corporation Announces Pricing and Upsizing of Tender Offer

AmerisourceBergen

Johnson & Johnson

Attorney generals of several states reach settlement deal with J&J (JNJ) and three drug distributors - MCK, CAH and ABC - related to thousands of opioid abuse litigations. Non-participating states may join the deal soon.

US States Get $26B Settlement Deal in Opioid Abuse Litigation

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) (the “Company”) today announced the early tender results as of the Early Tender Time (as defined below) in connection with its previously announced cash tender offer to purchase up to $500,000,000 (subject to increase, the “Tender Cap”) aggregate principal amount (the “Offer”) of its outstanding 6.00% Notes due 2041 (the “6.00% Notes”), 4.883% Notes due 2044 (the “4.883% Notes”), 7.65% Debentures due 2027 (the “7.65% Debentures”),

McKesson Corporation Announces Early Tender Results and Intention to Increase the Tender Cap

States unveiled a historic $26 billion settlement with drug companies to resolve thousands of opioid-crisis lawsuits, paving the way for communities across the country to secure a jolt of funding to address an epidemic in painkiller addiction that hasn't abated.

The Wall Street Journal: States announce $26 billion settlement to resolve opioid lawsuits

CONSHOHOCKEN, Pa. & DUBLIN, Ohio & IRVING, Texas--(BUSINESS WIRE)--AmerisourceBergen (NYSE: ABC), Cardinal Health (NYSE: CAH) and McKesson (NYSE: MCK) announced today that they have negotiated a comprehensive proposed settlement agreement which, if all conditions are satisfied, would result in the settlement of a substantial majority of opioid lawsuits filed by state and local governmental entities. While the companies strongly dispute the allegations made in these lawsuits, they believe the pr

Distributors Announce Proposed Opioid Settlement Agreement

McKesson (MCK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

McKesson (MCK) Soars 3.2%: Is Further Upside Left in the Stock?

The three largest U.S. drug distributors agreed mid-trial to pay up to $1.18 billion to settle claims by New York state and two of its biggest counties over their role in the nationwide opioid epidemic, the state's attorney general said on Tuesday. McKesson, Cardinal Health and AmerisourceBergen settled as state attorneys general prepare to announce.

Drug distributors agree to settle New York opioid claims for up to $1.18B

NEW YORK, July 20 (Reuters) - The three largest U.S. drug distributors agreed mid-trial to pay up to $1.18 billion to settle claims by New York state and two of its biggest counties over their role in the nationwide opioid epidemic, the state's attorney general said on Tuesday.

Drug distributors settle New York opioid claims for up to $1.18 bln

McKesson Corporation (NYSE: MCK), Cardinal Health Inc (NYSE: CAH), and AmerisourceBergen Corp (NYSE: ABC) have agreed to pay up to $1.179 billion to settle claims by New York state and two of its biggest counties over their role in the U.S. opioid epidemic. The drug distributors settled as state attorneys general prepare to announce a $26 billion deal with the distributors and drugmaker Johnson & Johnson (NYSE: JNJ), resolving cases as soon as this week.

Drug Distributors To Pay Up To $1.1B To Settle New York Opioid Claims

Shares of McKesson Corp. , Cardinal Health Inc. and AmerisourceBergen Corp. all surged more than 4% in morning trading Tuesday, after the New York Attorney General Letitia James announced a $1.1 billion settlement agreement with the drug distributors to combat the opioid epidemic. James said the agreement resolves claims for the companies' role in helping fuel the epidemic, and will remove the companies from the ongoing opioid trial.

McKesson, Cardinal Health, AmerisourceBergen stocks surge after $1.1 billion opioid settlement with NY AG

CENTRAL ISLIP, N.Y.--(BUSINESS WIRE)--AmerisourceBergen (NYSE: ABC), Cardinal Health (NYSE: CAH) and McKesson (NYSE: MCK) announced today that they have agreed to pay up to $1.179 billion in a settlement with the State of New York and its participating subdivisions, including Nassau and Suffolk Counties, to resolve opioid-related claims. This settlement was negotiated in connection with the ongoing negotiations toward a broad resolution under the previously disclosed settlement framework intend

Distributors Reach Opioid Settlement Agreement With New York State

D.R. Horton

Gartner

Omnicom Group

Vishay Intertechnology

Markets carried over Friday's red performance this morning by starting off the week dropping between 1 and 1.5% on the open, with the Dow underperforming the most. Make the most of it with the Top Buys from Q.ai's artificial intelligence.

D R Horton Inc Ranked Among Today's Top Buys

West Pharmaceutical Services

Despite the COVID-19 pandemic induced challenges, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical-Dental Supplies industry. MCK, WST and CAH are well-poised to gain from the prospects.

News for McKesson Stock (MCK)